Langsiktig oppfølgingsstudie av RGX-314 administrert i det suprakoroidale rommet for deltakere med diabetisk retinopati
En langsiktig oppfølgingsstudie for å evaluere sikkerheten og effektiviteten av suprakoroidal administrering av RGX-314 for diabetisk retinopati uten senterinvolvert-diabetisk makulært ødem
This is a prospective study designed to evaluate the long-term safety and efficacy of ABBV-RGX-314. Eligible participants are those who were previously enrolled in a clinical study of DR with and without center involved-diabetic macular edema (CI-DME) in which they received suprachoroidal space (SCS) administration of ABBV-RGX-314. Enrollment of each participant in the current study should occur after the participant has completed either the end of study or early discontinuation visit in the previous (parent) clinical study. Participants will be followed for a total of 5 years post-ABBV-RGX-314 administration (inclusive of the parent study). As such, the total study duration for each participant may vary depending on when they enroll in the current study following ABBV-RGX-314 administration in the parent study.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Studietype
Studietype
Registrering (Faktiske)
Registrering
Fase
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
Arizona
-
Phoenix, Arizona, Forente stater, 85014
- Retinal Research Institute, LLC
-
-
California
-
Bakersfield, California, Forente stater, 93309
- California Retina Consultants
-
Beverly Hills, California, Forente stater, 90211
- Retina-Vitreous Associates Medical Group
-
Los Angeles, California, Forente stater, 90017
- Retinal Diagnostic Center
-
Mountain View, California, Forente stater, 94040
- Northern California Retina Vitreous Associates Medical Group Inc
-
Pasadena, California, Forente stater, 91107
- California Eye Specialists Medical Group, Inc
-
Poway, California, Forente stater, 92064
- Retina Consultants San Diego
-
Santa Barbara, California, Forente stater, 93103
- California Retina Consultants CRC
-
-
Georgia
-
Augusta, Georgia, Forente stater, 30909
- Southeast Retina Center, PC
-
-
Illinois
-
Oak Forest, Illinois, Forente stater, 60452
- University Retina and Macula Associates, PC
-
-
Maryland
-
Hagerstown, Maryland, Forente stater, 21740
- Cumberland Valley Retina Consultants
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02114
- Ophthalmic Consultants of Boston
-
-
Nevada
-
Reno, Nevada, Forente stater, 89502
- Sierra eye Associates
-
-
New Jersey
-
Teaneck, New Jersey, Forente stater, 07666
- New Jersey Retina
-
-
New Mexico
-
Albuquerque, New Mexico, Forente stater, 87109
- Vision Research Center Eye Associates of New Mexico
-
-
North Carolina
-
Durham, North Carolina, Forente stater, 27705
- Duke University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19107
- Mid Atlantic Retina
-
-
Tennessee
-
Germantown, Tennessee, Forente stater, 38138
- Charles Retina Institute, P.C
-
-
Texas
-
Austin, Texas, Forente stater, 78750
- Austin Clinical Research
-
The Woodlands, Texas, Forente stater, 77384
- Retina Consultants of Texas
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
- Voksen
- Eldre voksen
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Must provide written, signed informed consent for this study
- Must have been enrolled in a previous clinical study of ABBV-RGX-314 for the treatment of DR with or without CI-DME and must have received an SCS injection of ABBV-RGX-314 in that study
- Must be willing and able to comply with all study procedures
Exclusion Criteria:
- None
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Annen: Standard of Care
Dose Level (DL) 1-3 participants who received ABBV-RGX-314 in a parent study will continue to receive standard of care for the study duration. |
Standard of Care |
|
Annen: Supplemental Treatment
DL4 participants from parent study will be eligible to receive supplement aflibercept through a prespecified timepoint based on protocol-specified criteria if they develop worsening CI-DME or high-risk proliferative diabetic retinopathy (PDR) in the study eye. |
Standard of Care Injection
Andre navn:
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of ocular adverse events (AEs) and any serious adverse events (SAEs)
Tidsramme: 5 years inclusive of the parent study
|
To evaluate the long-term safety of ABBV-RGX-314 |
5 years inclusive of the parent study
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Andel deltakere som trenger ytterligere intervensjon for okulære diabetiske komplikasjoner (f.eks. anti-VEGF intravitreal injeksjon eller PRP)
Tidsramme: 5 år, inkludert foreldrestudiet
|
5 år, inkludert foreldrestudiet
|
|
Andel deltakere med eventuelle synstruende okulære diabetiske komplikasjoner
Tidsramme: 5 år, inkludert foreldrestudiet
|
5 år, inkludert foreldrestudiet
|
|
Incidences of non-ocular AEs and any Adverse Events of Special Interest
Tidsramme: 5 years, inclusive to the parent study
|
5 years, inclusive to the parent study
|
|
Mean change from baseline (ie, prior to ABBV-RGX-314 administration in the parent study) in DR by ETDRS-DRSS on digital stereoscopic fundus photography
Tidsramme: 5 years, inclusive of the parent study
|
5 years, inclusive of the parent study
|
|
Proportion of participants achieving 0-step (no change), a ≥1-step, a ≥2-step, or a ≥3-step or greater change in DR per ETDRS-DRSS on digital stereoscopic fundus photography from baseline (ie, prior to ABBV-RGX-314 administration in the parent study)
Tidsramme: 5 years, inclusive to the parent study
|
5 years, inclusive to the parent study
|
|
Mean change from baseline (ie, prior to ABBV-RGX-314 administration in the parent study) in BCVA
Tidsramme: 5 years, inclusive to the parent study
|
5 years, inclusive to the parent study
|
|
Proportion of participants gaining or losing ≥ 5, 10, and 15 letters in BCVA compared with baseline (ie, prior to ABBV-RGX-314 administration in the parent study)
Tidsramme: 5 years, inclusive to the parent study
|
5 years, inclusive to the parent study
|
|
Mean change from baseline (ie, prior to ABBV-RGX-314 administration in the parent study) in CST as measured by SD-OCT
Tidsramme: 5 years, inclusive to the parent study
|
5 years, inclusive to the parent study
|
|
Mean change from baseline (ie, prior to ABBV-RGX-314 administration in the parent study) in the area of retinal nonperfusion on ultra-widefield Optos FA
Tidsramme: 5 years, inclusive to the parent study
|
5 years, inclusive to the parent study
|
|
Mean number of anti-VEGF injections through years 2, 3, 4, and 5 based on ongoing chart review in the study eye (DL4 participants only)
Tidsramme: 5 years, inclusive to the parent study
|
5 years, inclusive to the parent study
|
|
Mean number of anti-VEGF injections in years 2, 3, 4, and 5 based on ongoing chart review in the study eye (DL4 participants only)
Tidsramme: 5 years, inclusive to the parent study
|
5 years, inclusive to the parent study
|
|
Mean anti-VEGF injection annualized rate through years 2, 3, 4, and 5 based on ongoing chart review in the study eye (DL4 participants only)
Tidsramme: 5 years, inclusive to the parent study
|
5 years, inclusive to the parent study
|
|
Mean anti-VEGF injection annualized rate in years 2, 3, 4, and 5 based on ongoing chart review in the study eye (DL4 participants only)
Tidsramme: 5 years, inclusive to the parent study
|
5 years, inclusive to the parent study
|
|
Mean number of retina specialist visits attended for complications of DR based on chart review
Tidsramme: 5 years, inclusive to the parent study
|
5 years, inclusive to the parent study
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Samarbeidspartnere
Samarbeidspartnere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Sykdommer i det endokrine systemet
- Vaskulære sykdommer
- Kardiovaskulære sykdommer
- Sukkersyke
- Øyesykdommer
- Diabetiske angiopatier
- Diabetes komplikasjoner
- Retinale sykdommer
- Diabetisk retinopati
- Health Services Administration
- Helsevesenets kvalitet, tilgang og evaluering
- Kvalitet på helsehjelpen
- Kvalitetsindikatorer, helsehjelp
- Standard for omsorg
- aflibercept
Andre studie-ID-numre
Andre studie-ID-numre
- RGX-314-5201 (M23-420)
- M23-420 (Annen identifikator: AbbVie Inc)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
IPD-delingstidsramme
For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
Tilgangskriterier for IPD-deling
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .